David Mazzo, PHD

David J. Mazzo, Ph.D. joined Caladrius Biosciences (Nasdaq: CLBS) as its Chief Executive Officer and as a member of the Caladrius Board of Directors in January 2015. Dr. Mazzo brings to Caladrius over 35 years of international experience in the pharmaceutical industry developing and launching new products in all therapeutic areas. Prior to joining Caladrius, Dr. Mazzo served from August 2008 to October 2014 as Chief Executive Officer and as a member of the Board of Directors of Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the development of novel antithrombotic drug systems for acute and sub-acute cardiovascular indications. Prior to his leading Regado, from March 2007 to April 2008, Dr. Mazzo was President, Chief Executive Officer and a director of Æterna Zentaris, Inc. (Nasdaq: AEZS), a publicly held international biopharmaceutical company. From 2003 until 2007, Dr. Mazzo served as President, Chief Executive Officer and a director of Chugai Pharma USA, LLC, a biopharmaceutical company which was the U.S. subsidiary of Chugai Pharmaceutical Co., Ltd. of Japan, a member of the Roche Group (Switzerland). Dr. Mazzo has also held senior management and executive positions in research and development and was a director of the Essex Chimie European subsidiary at Schering-Plough Corporation, a publicly held international pharmaceutical company that was subsequently acquired by Merck & Co., Inc.; Hoechst Marion Roussel, Inc., the US subsidiary of Hoechst AG, which was subsequently acquired by Sanofi, a multinational pharmaceuticals company; and Rhone-Poulenc Rorer, Inc., a subsidiary of Rhone-Poulenc SA, a French pharmaceuticals company, which was subsequently acquired by Hoechst AG. He also has amassed many years of experience serving as an independent director of public company boards of directors including, from August 2005 to January 2015, Avanir Pharmaceuticals, Inc., (Nasdaq: AVNR) a biotechnology company with a focus on new treatments for diseases of the central nervous system, which was sold to Otsuka Holdings in 2015 and, from August 2005 to June 2015, EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) a publicly held biopharmaceutical company focused on new products in ophthalmology. Since February 2020, Dr, Mazzo has been a member of the board of directors of VTI, Inc., (ASX: VTI) an international developer and seller of therapeutic contact lenses, where he joined as and remains chairman and Seneca Biopharmaceuticals, Inc., (Nasdaq: SNCA) a therapeutics development company focused on new treatments for serious diseases, where he has served on the board since April 2019. Dr. Mazzo earned a B.A. in the Honors Program (Interdisciplinary Humanities) and a B.S. in Chemistry from Villanova University. In addition, Dr. Mazzo received his M.S. in chemistry and his Ph.D. degree in Analytical Chemistry from the University of Massachusetts, Amherst. Completing his formal education, he was also a research fellow at the Ecole Polytechnique Federale de Lausanne, Switzerland.